| Nome |
# |
|
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience, file e27ce426-fc98-2581-e053-d805fe0acbaa
|
491
|
|
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis, file e27ce42f-0acf-2581-e053-d805fe0acbaa
|
427
|
|
Telemedicine in Parkinson's Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic, file e27ce430-c823-2581-e053-d805fe0acbaa
|
291
|
|
Natalizumab in Multiple Sclerosis: Long-Term Management, file e27ce42b-2a28-2581-e053-d805fe0acbaa
|
282
|
|
Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients., file e27ce426-f234-2581-e053-d805fe0acbaa
|
258
|
|
Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients., file e27ce426-d803-2581-e053-d805fe0acbaa
|
255
|
|
Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients, file e27ce426-fafc-2581-e053-d805fe0acbaa
|
158
|
|
Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail, file e27ce430-c825-2581-e053-d805fe0acbaa
|
144
|
|
Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: Findings from an Italian independent registry, file e27ce42b-1979-2581-e053-d805fe0acbaa
|
131
|
|
Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome?, file e27ce426-fa3d-2581-e053-d805fe0acbaa
|
127
|
|
Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients: a 15 months follow-up study., file e27ce426-d9a8-2581-e053-d805fe0acbaa
|
116
|
|
80 Hz versus 130 Hz subthalamic nucleus deep brain stimulation: effects on involuntary movements., file e27ce426-e613-2581-e053-d805fe0acbaa
|
90
|
|
Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset?, file e27ce426-dbf5-2581-e053-d805fe0acbaa
|
87
|
|
Pisa syndrome in Parkinson's disease is associated with specific cognitive alterations, file e27ce42e-9c97-2581-e053-d805fe0acbaa
|
85
|
|
Neurological comorbidity and severity of COVID-19, file e27ce430-805e-2581-e053-d805fe0acbaa
|
85
|
|
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study, file e27ce430-e6fe-2581-e053-d805fe0acbaa
|
84
|
|
Safety and efficacy of tolcapone in Parkinson’s disease: systematic review, file e27ce431-9d12-2581-e053-d805fe0acbaa
|
84
|
|
Telemedicine and the challenge of epilepsy management at the time of COVID-19 pandemic, file e27ce430-c821-2581-e053-d805fe0acbaa
|
81
|
|
SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review, file 06a68f3e-9f70-428b-adc6-698f9d656621
|
78
|
|
Motor and non-motor outcomes of subthalamic deep brain stimulation in a case of juvenile PARK-PINK1, file e27ce432-06a3-2581-e053-d805fe0acbaa
|
61
|
|
The still under-investigated role of cognitive deficits in PML diagnosis, file e27ce430-9ee2-2581-e053-d805fe0acbaa
|
56
|
|
Digital work engagement among Italian neurologists, file e27ce434-ae6d-2581-e053-d805fe0acbaa
|
56
|
|
Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: Findings from an Italian independent registry, file e27ce42c-0d4d-2581-e053-d805fe0acbaa
|
49
|
|
Deep Brain Stimulation Selection Criteria for Parkinson's Disease: Time to Go beyond CAPSIT-PD, file e27ce431-0668-2581-e053-d805fe0acbaa
|
43
|
|
Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic, file e27ce432-6a9c-2581-e053-d805fe0acbaa
|
19
|
|
Changing the Side of Pisa Syndrome: A Case of Over-Recovery with Botulinum Toxin, file e27ce430-8d72-2581-e053-d805fe0acbaa
|
18
|
|
Levodopa-Induced Dyskinesias and Dyskinesias-Reduced-Self-Awareness in Parkinson’s Disease: A Neurocognitive Approach, file c6d96bba-317e-4248-8358-493a7a1bf370
|
16
|
|
Time to onset and duration of botulinum toxin efficacy in movement disorders, file e27ce434-b875-2581-e053-d805fe0acbaa
|
12
|
|
G325R GBA mutation in Parkinson's disease: Disease course and long-term DBS outcome, file e27ce434-7488-2581-e053-d805fe0acbaa
|
11
|
|
Earlier versus later subthalamic deep brain stimulation in Parkinson's disease, file e27ce427-c97f-2581-e053-d805fe0acbaa
|
9
|
|
Improving the care of Rebif® treated Multiple Sclerosis patients: the "MSdialog" experience, file e27ce430-b2fb-2581-e053-d805fe0acbaa
|
8
|
|
Effects of dopaminergic therapy on sleep quality in fluctuating Parkinson’s disease patients, file d299bc55-ed3a-4d74-95ea-0c96254e67e5
|
7
|
|
80 Hz versus 130 Hz subthalamic nucleus deep brain stimulation: effects on involuntary movements., file e27ce426-e612-2581-e053-d805fe0acbaa
|
7
|
|
Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis, file e27ce430-82ad-2581-e053-d805fe0acbaa
|
6
|
|
Burden of caregiving for cardiovascular dysautonomia in Parkinson's disease, file 5b38ade5-0d36-4383-b9c3-01953be11c0d
|
5
|
|
Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients., file e27ce426-f50a-2581-e053-d805fe0acbaa
|
5
|
|
Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study, file e27ce42e-8285-2581-e053-d805fe0acbaa
|
5
|
|
Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome?, file e27ce426-fa3c-2581-e053-d805fe0acbaa
|
4
|
|
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience, file e27ce426-fc97-2581-e053-d805fe0acbaa
|
3
|
|
Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study, file e27ce427-a4d3-2581-e053-d805fe0acbaa
|
3
|
|
Parkinsonism–hyperpyrexia syndrome and deep brain stimulation, file e27ce428-34b3-2581-e053-d805fe0acbaa
|
3
|
|
Focal seizures with impaired awareness as long-term neurological complication of COVID-19: a case report, file e27ce431-c36b-2581-e053-d805fe0acbaa
|
3
|
|
Deep brain stimulation fine-tuning in Parkinson's disease: Short pulse width effect on speech, file e27ce432-613f-2581-e053-d805fe0acbaa
|
3
|
|
Gait and axial postural abnormalities correlations in Parkinson's disease: A multicenter quantitative study, file a9a14509-1abb-42cb-a50d-0f7fc13e9329
|
2
|
|
15-Year Subthalamic Deep Brain Stimulation outcome in a Parkinson’s disease patient with Parkin gene mutation: a case report, file c780680d-7b1a-4239-9f98-74f77a27a817
|
2
|
|
Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset?, file e27ce426-dbf4-2581-e053-d805fe0acbaa
|
2
|
|
Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients, file e27ce426-fafa-2581-e053-d805fe0acbaa
|
2
|
|
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab, file e27ce42b-4fc4-2581-e053-d805fe0acbaa
|
2
|
|
Low frequency subthalamic stimulation and event-related potentials in Parkinson disease, file e27ce431-066a-2581-e053-d805fe0acbaa
|
2
|
|
How resistant are levodopa-resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease, file 111e24df-a6d8-4b27-8110-b7b3a1ac32ca
|
1
|
|
Telemedicine and the challenge of epilepsy management at the time of COVID-19 pandemic, file 2c59e11b-028c-47e8-8399-c69976b995a4
|
1
|
|
Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients: a 15 months follow-up study., file e27ce426-d9a7-2581-e053-d805fe0acbaa
|
1
|
|
Beyond Nine Years of Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease, file e27ce428-44aa-2581-e053-d805fe0acbaa
|
1
|
|
Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients., file e27ce428-4c91-2581-e053-d805fe0acbaa
|
1
|
|
Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases, file e27ce42c-61b6-2581-e053-d805fe0acbaa
|
1
|
|
Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects, file e27ce42d-2bac-2581-e053-d805fe0acbaa
|
1
|
|
Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study, file e27ce42d-3ef9-2581-e053-d805fe0acbaa
|
1
|
|
Telemedicine in Neurological Disorders: Opportunities and Challenges, file e27ce42d-53b7-2581-e053-d805fe0acbaa
|
1
|
|
Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study, file e27ce42d-972c-2581-e053-d805fe0acbaa
|
1
|
|
Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson’s disease, file e27ce42e-653c-2581-e053-d805fe0acbaa
|
1
|
|
Levodopa-Induced Neuropathy: A Systematic Review, file e27ce42e-8281-2581-e053-d805fe0acbaa
|
1
|
|
Complex therapies for advanced Parkinson’s disease: what is the role of doctor-patient communication?, file e27ce42e-9c98-2581-e053-d805fe0acbaa
|
1
|
|
Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential, file e27ce430-805d-2581-e053-d805fe0acbaa
|
1
|
|
Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia, file e27ce430-820d-2581-e053-d805fe0acbaa
|
1
|
|
COVID-19 in Parkinson's disease: Report on prevalence and outcome, file e27ce430-8d6e-2581-e053-d805fe0acbaa
|
1
|
|
COVID-19 and Parkinson's Disease: What We Know So Far?, file e27ce431-ae81-2581-e053-d805fe0acbaa
|
1
|
|
Deep brain stimulation outcomes in the malignant end of Parkinson's disease spectrum, file e27ce431-c368-2581-e053-d805fe0acbaa
|
1
|
|
Ventral Tegmental Area Disconnection Contributes Two Years Early to Correctly Classify Patients Converted to Alzheimer's Disease: Implications for Treatment, file e27ce432-3341-2581-e053-d805fe0acbaa
|
1
|
|
Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study, file e27ce432-535d-2581-e053-d805fe0acbaa
|
1
|
|
Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis, file e27ce432-571f-2581-e053-d805fe0acbaa
|
1
|
|
Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases, file e27ce432-617d-2581-e053-d805fe0acbaa
|
1
|
|
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease, file e27ce434-902b-2581-e053-d805fe0acbaa
|
1
|
| Totale |
3.801 |